About Melinta Therapeutics
Melinta Therapeutics is a company based in Morristown (United States) founded in 2000 was acquired by CorMedix in August 2025.. Melinta Therapeutics has raised $186 million across 15 funding rounds from investors including Hercules Capital, Sanofi and Warburg Pincus. Melinta Therapeutics offers products and services including Innovative Therapies and Portfolio Products. Melinta Therapeutics operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Iterum Therapeutics, Adaptive Phage Therapeutics and Cubist Pharmaceuticals, among others.
- Headquarter Morristown, United States
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Melinta Therapeutics, Llc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$186 M (USD)
in 15 rounds
-
Latest Funding Round
$75 M (USD), Post-IPO
Feb 22, 2019
-
Investors
Hercules Capital
& 16 more
-
Employee Count
Employee Count
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Melinta Therapeutics
Melinta Therapeutics offers a comprehensive portfolio of products and services, including Innovative Therapies and Portfolio Products. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapies targeting acute and life-threatening illnesses for patient care.
Commercial-stage products for expanding healthcare applications.
Unlock access to complete
Unlock access to complete
Funding Insights of Melinta Therapeutics
Melinta Therapeutics has successfully raised a total of $186M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $75 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 15
- Last Round Post-IPO — $75.0M
-
First Round
First Round
(31 Dec 2001)
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2019 | Amount | Post-IPO - Melinta Therapeutics | Valuation |
investors |
|
| Jan, 2018 | Amount | Post-IPO - Melinta Therapeutics | Valuation |
investors |
|
| Nov, 2017 | Amount | Post-IPO - Melinta Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Melinta Therapeutics
Melinta Therapeutics has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, Sanofi and Warburg Pincus. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Structured financing solutions are provided for the global healthcare industry by Oberland Capital.
|
Founded Year | Domain | Location | |
|
Venture debt financing is provided to companies in multiple sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Melinta Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Melinta Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Melinta Therapeutics Comparisons
Competitors of Melinta Therapeutics
Melinta Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Iterum Therapeutics, Adaptive Phage Therapeutics and Cubist Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| domain | founded_year | HQ Location |
Developer of antibiotics for MDR infections
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| domain | founded_year | HQ Location |
Pharmaceuticals for acute care bacterial infections are developed and commercialized.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Melinta Therapeutics
Frequently Asked Questions about Melinta Therapeutics
When was Melinta Therapeutics founded?
Melinta Therapeutics was founded in 2000 and raised its 1st funding round 1 year after it was founded.
Where is Melinta Therapeutics located?
Melinta Therapeutics is headquartered in Morristown, United States. It is registered at Morristown, New Jersey, United States.
Who is the current CEO of Melinta Therapeutics?
Christine Ann Miller is the current CEO of Melinta Therapeutics.
Is Melinta Therapeutics a funded company?
Melinta Therapeutics is a funded company, having raised a total of $186M across 15 funding rounds to date. The company's 1st funding round was a Post-IPO of $132.91M, raised on Dec 31, 2001.
What does Melinta Therapeutics do?
Melinta Therapeutics is developing bacterial ribosome-targeting drugs for MDR infections. The company has commercialized its antibiotic, delafloxacin for acute bacterial skin and skin structure infections (Staphylococcus strains, Streptococcus strains, Enterococcus strain, E.coli, Enterobacter cloacae, Klebsiella pneumoniae, and P.aeruginosa), community-acquired bacterial pneumonia (CABP), and Complicated Urinary Tract Infections (cUTI). It is also developing a new class of antibiotics designed to overcome the resistant ESKAPE pathogens that cause hospital infections.
Who are the top competitors of Melinta Therapeutics?
Melinta Therapeutics's top competitors include Spero Therapeutics, Vedanta Biosciences and Cubist Pharmaceuticals.
What products or services does Melinta Therapeutics offer?
Melinta Therapeutics offers Innovative Therapies and Portfolio Products.
Who are Melinta Therapeutics's investors?
Melinta Therapeutics has 17 investors. Key investors include Hercules Capital, Sanofi, Warburg Pincus, CorMedix, and Vatera Healthcare Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.